Key result
Recombinant human growth hormone (rhGH) therapy improves height in children with idiopathic short stature, although its efficacy varies depending on underlying genetic mechanisms.
Why the study?
The genetic factors associated with idiopathic short stature are complex, and the efficacy of recombinant human growth hormone treatment varies among children with different genetic mechanisms.
Does recombinant human growth hormone therapy improve height in children with idiopathic short stature?
Does recombinant human growth hormone therapy improve height in children with idiopathic short stature?
Recombinant human growth hormone therapy is an effective clinical method for improving height in children with idiopathic short stature, though efficacy varies based on underlying genetic mechanisms.
Response to rhGH in ISS is genetically heterogeneous; hypothesis-generating for genotype-guided therapy pending prospective trials.
Idiopathic short stature (ISS) is a term that encompasses a group of short stature disorders with unknown etiology. The genetic factors associated with ISS are complex, and the known genetic mechanisms include alterations in hormones, hormone receptors, or related pathways, defects in fundamental cellular processes (such as intracellular signaling pathways and transcriptional regulation), issues with extracellular matrix or paracrine signaling, as well as genetic variations in the genes encoding these proteins. Recombinant human growth hormone (rhGH) therapy is currently an effective clinical method for improving height in children with ISS. However, the efficacy of rhGH treatment on ISS varies among children with different genetic mechanisms. This paper analyzes and elucidates the genetic mechanisms of ISS and the effects of rhGH on ISS based on existing clinical research, aiming to enhance the understanding of ISS and provide references for improving the height of these children.
No takes yet. Share an insight, caveat, or question.
M Mamat (2024) conducted a review in Idiopathic short stature (ISS). Recombinant human growth hormone (rhGH) was evaluated. Recombinant human growth hormone (rhGH) therapy improves height in children with idiopathic short stature, although its efficacy varies depending on underlying genetic mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: